Exelixis v. Biocon Pharma: Cabozantinib Patent Dispute Dismissed Without Prejudice
Exelixis, Inc. filed suit in Delaware District Court against Biocon Pharma over five patents protecting cabozantinib (S)-malate, the active ingredient in CABOMETYX®. The parties stipulated to dismissal without prejudice under Rule 41 after 147 days, with the court retaining jurisdiction to enforce related settlement agreements — suggesting a negotiated resolution rather than a litigated outcome.
Five-Patent Cabozantinib Dispute Ends in Stipulated Dismissal
Exelixis, Inc., the oncology company holding the commercial rights to CABOMETYX® (cabozantinib), filed this infringement action on April 11, 2025, in the District of Delaware before Judge Richard G. Andrews. The complaint asserted five U.S. patents — US8877776B2, US11091440B2, US11098015B2, US12128039B2, and US11091439B2 — against Biocon Pharma, Ltd. and affiliated Biocon entities. The dispute arose from Biocon’s filing of an abbreviated new drug application (ANDA) seeking approval to market generic cabozantinib (S)-malate tablets in 20 mg, 40 mg, and 60 mg strengths.
The case closed on September 5, 2025, via a joint stipulation of dismissal without prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). Critically, the stipulation expressly states the court retains jurisdiction to enforce ‘the parties’ related agreements resolving this matter’ — language that strongly suggests the parties reached a private settlement agreement, potentially including a negotiated entry date for Biocon’s generic product, rather than litigating through the Hatch-Waxman 30-month stay period.
A resolution after just 147 days is notably swift for a multi-patent Hatch-Waxman case in Delaware, where contested ANDA litigation routinely extends two to three years. The compressed timeline, combined with the ‘without prejudice’ designation and the court’s retained jurisdiction, is consistent with a confidential license or consent judgment. The specific terms — including any agreed launch date for Biocon’s generic — remain undisclosed in the public record.
Filing to Dismissed without Prejudice in 147 days
147 days — resolved before any substantive motion practice in this ANDA patent dispute
Stipulated dismissal without prejudice: what this resolution means for both parties
Rule 41(a)(1)(A)(ii): joint stipulation, no court adjudication
A dismissal under Rule 41(a)(1)(A)(ii) is agreed by both parties and requires no court order. ‘Without prejudice’ means Exelixis technically retains the right to refile on the same patents. The court’s express retention of jurisdiction to enforce ‘related agreements’ is the operative signal — it indicates a binding side agreement (likely a settlement or license) exists and will be judicially enforceable.
No merits adjudicatedExelixis preserves patent portfolio and enforcement rights
A without-prejudice dismissal leaves all five asserted patents intact and unchallenged on the merits. Exelixis avoids any judicial finding of invalidity or non-infringement. If a license was granted, Exelixis likely secured royalties or a controlled entry date protecting the commercial life of CABOMETYX®. The patents remain fully enforceable against other potential generic entrants.
Patents remain enforceableBiocon avoids a trial loss but gains no invalidity ruling
Biocon obtains no declaratory judgment of invalidity or non-infringement — a common goal for ANDA filers seeking a clear path to market. Without a public court ruling, Biocon cannot use this outcome to clear the path for other generic manufacturers. Any market access Biocon secured is likely governed by a private agreement, the terms of which are not in the public record.
No invalidity ruling securedCABOMETYX® exclusivity timeline remains opaque to the market
Because the settlement terms are private, other ANDA filers and market participants cannot determine Biocon’s agreed launch date or the scope of any license. This opacity is commercially significant: if Biocon is a first-to-file ANDA filer, its settlement terms could affect 180-day exclusivity rights available to other generics. Competing oncology generics developers should monitor FDA ANDA databases and any subsequent 30-month stay filings closely.
Generic entry date undisclosedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Exelixis, Inc. | Company | Oncology biopharmaceutical company — holder of US8877776B2 and 4 further cabozantinib patentsSearch in Eureka ↗ |
| Defendant | Biocon Pharma, Ltd. | Company | Indian pharmaceutical manufacturer seeking ANDA approval for generic cabozantinib (S)-malate tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Gorka | Attorney | Counsel for Exelixis, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Amy K. Wigmore | Attorney | Counsel for Exelixis, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Anna Mizzi | Attorney | Counsel for Exelixis, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Anthony David Raucci | Attorney | Counsel for Exelixis, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Cindy Kan | Attorney | Counsel for Exelixis, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Emily R. Whelan | Attorney | Counsel for Exelixis, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gerard A. Salvatore | Attorney | Counsel for Exelixis, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jonathan A. Cox | Attorney | Counsel for Exelixis, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kevin S. Prussia | Attorney | Counsel for Exelixis, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lisa J. Pirozzolo | Attorney | Counsel for Exelixis, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Rodger Dallery Smith , II | Attorney | Counsel for Exelixis, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Exelixis, Inc.Search in Eureka ↗ |
| Defendant counsel | Jeremy J. Edwards | Attorney | Counsel for Biocon Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | John C. Phillips , Jr. | Attorney | Counsel for Biocon Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | Megan C. Haney | Attorney | Counsel for Biocon Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | Steven A. Maddox | Attorney | Counsel for Biocon Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Biocon Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation’s reference to ‘the parties’ related agreements resolving this matter’ is legally significant language in a Rule 41 dismissal — it signals that the dismissal is not a pure walk-away but the procedural vehicle for implementing a binding private resolution, likely a patent license or consent judgment. The court’s explicit retention of jurisdiction transforms what is nominally a voluntary dismissal into an enforceable framework. Neither party obtained a merits ruling, meaning the validity and infringement questions on all five cabozantinib patents remain judicially unresolved.
US8877776B2 — Cabozantinib (S)-malate compound and formulation patents
US8877776B2, the earliest asserted patent (application filed 2011, corresponding to US13/145054), covers the cabozantinib (S)-malate compound that is the active pharmaceutical ingredient in CABOMETYX®. The four later patents — US11091440B2, US11098015B2, US11091439B2, and US12128039B2 — extend protection across formulation, method-of-use, and manufacturing dimensions, with the most recent (US12128039B2, application US18/436836) appearing to have been filed in 2024, suggesting active continuation prosecution. Together, the five patents form a layered exclusivity structure characteristic of lifecycle management in branded oncology.
CABOMETYX® generated over $1.4 billion in net product revenues for Exelixis in 2023, making it one of the most commercially significant oncology assets subject to generic challenge. The breadth of the asserted portfolio — spanning compound, formulation, and potentially method claims across five distinct patent numbers — reflects a deliberate strategy to raise the cost and complexity of any ANDA filer’s invalidity challenge. For competing oncology generics developers, the 2024-filed continuation patent is a particularly important signal that Exelixis may continue to expand its IP perimeter around cabozantinib.
Should you run an FTO analysis against Exelixis’ cabozantinib patent portfolio?
Any pharmaceutical or biotechnology company developing a generic or biosimilar version of cabozantinib (S)-malate — or a novel oncology compound with overlapping mechanism-of-action claims — should treat this five-patent portfolio as a high-priority FTO target. The presence of a 2024-filed continuation (US12128039B2) indicates the patent family is still in active prosecution, and claims may still be pending that could be tailored to cover competing formulations or manufacturing processes.
PatSnap Eureka’s FTO Search Agent can map all five asserted patents, identify related family members and pending continuations, and generate a claim chart comparing Exelixis’ claim scope against your product’s composition and process parameters. Eureka also monitors new publications in the cabozantinib patent family in real time — critical for any ANDA developer who needs early warning of newly issued claims before committing to a product development pathway.
Run a freedom-to-operate analysis on US8877776B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman cabozantinib and oncology ANDA cases in Delaware
Delaware District Court is the primary venue for Hatch-Waxman oncology patent disputes. These cases share the cabozantinib IP landscape or analogous multi-patent ANDA litigation dynamics.
What this case signals for the cabozantinib generic IP landscape
A 147-day resolution of a five-patent ANDA suit signals either commercial pragmatism or strategic positioning — both warrant close monitoring.
Early settlement in Hatch-Waxman cases often reflects negotiated launch dates
When an ANDA patent suit resolves in under 150 days with court-retained jurisdiction, the most common explanation is a licensed entry agreement. Brand holders typically negotiate a future date for generic launch that preserves peak exclusivity revenue. Other generics developers should treat this as a signal that Biocon may have secured preferential market access terms.
Five patents asserted — portfolio breadth deters merits challenges
Exelixis deployed five patents spanning formulation and compound claims against Biocon’s ANDA. Litigating invalidity across that portfolio through trial is expensive and uncertain. For any pharmaceutical company developing a cabozantinib generic, this case illustrates the cost-benefit pressure to settle rather than challenge the full Exelixis portfolio in court.
Exelixis v Biocon — key questions answered
Exelixis asserted five U.S. patents: US8877776B2, US11091440B2, US11098015B2, US12128039B2, and US11091439B2. All relate to cabozantinib (S)-malate, the active ingredient in CABOMETYX® tablets (20 mg, 40 mg, 60 mg). The patents span compound, formulation, and related claims filed between 2011 and 2024.
The case resolved in 147 days via a Rule 41(a)(1)(A)(ii) stipulated dismissal without prejudice. The court’s retention of jurisdiction to enforce ‘related agreements resolving this matter’ strongly suggests the parties reached a private settlement — likely a patent license with a negotiated generic entry date — rather than litigating through the full Hatch-Waxman 30-month stay period.
No. A dismissal without prejudice is a procedural termination of the lawsuit and has no direct bearing on FDA’s review of Biocon’s ANDA. It means the patent infringement claims were not adjudicated on the merits. Biocon likely negotiated terms governing when and how it may launch its generic cabozantinib product, but those terms are not in the public court record.
Technically yes — a without-prejudice dismissal does not bar refiling on the same claims. However, the stipulation’s reference to ‘related agreements resolving this matter’ and the court’s retained jurisdiction suggest the parties have a binding resolution. A refile would likely only occur if Biocon breached that agreement, triggering the court’s enforcement jurisdiction.
Other ANDA filers face the same five-patent portfolio, which now has not been adjudicated as invalid or unenforceable. The lack of a public invalidity ruling means no judicial precedent benefits rival generics. Additionally, if Biocon holds first-filer status, its settlement may affect 180-day exclusivity availability. Competing generics developers should conduct fresh FTO analysis and monitor patent prosecution activity, particularly around the 2024-filed US12128039B2.
PatSnap Eureka searches patents and litigation data to answer instantly.